Physician profile
Vincent Patrick Devlin
NPI 1871910752
$4,918.53
in general payments reported to CMS, 2019-2025
21 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $654 · 2021: $207 · 2022: $2,019 · 2023: $690 · 2024: $463 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,392.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,448.48 | 2019-2025 | Tezspire, Fasenra |
| Genzyme Corporation | $884.01 | 2019-2024 | |
| Glaxosmithkline, LLC. | $616.02 | 2021-2023 | Nucala |
| Aimmune Therapeutics, INC. | $350.00 | 2020 | |
| Amgen INC. | $295.23 | 2022-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $294.34 | 2021-2023 | Dupixent |
| Biocryst US Sales Co., LLC | $177.51 | 2022-2025 | Orladeyo |
| Genentech USA, INC. | $140.38 | 2021-2025 | Xolair |
| Genentech, INC. | $129.75 | 2022-2024 | Xolair |
| Optinose US, INC. | $124.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $106.29 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $74.75 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.55 | 2020 | |
| Pfizer INC. | $67.47 | 2019-2020 | |
| Ventec Life Systems, INC. | $25.92 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jubilant Hollisterstier LLC | $25.24 | 2022 | |
| Csl Behring | $24.82 | 2020 | |
| Horizon Therapeutics Plc | $20.96 | 2020 | |
| Covis Pharma Gmbh | $16.62 | 2020 | |
| Grifols USA, LLC | $14.41 | 2024 | Gamunex-C |
| Kaleo, INC. | $11.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Devlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.